Dividend Win Wednesday: 7.6% FCF Yields and 47% Insider Buy Ratios in the Drawdown

This Week's Setup

The screen is stacked with pharma and materials names trading 15–34% below 52-week highs while generating FCF yields north of 4.5%. NEM at 6.3%, BIIB at 7.1%, and DLTR at 7.6% FCF yield pair with payout ratios under 50% or zero dividends, signaling cash flow headroom that hasn't yet been priced into depressed multiples.

Insider alignment is sharp across the list. BIIB insiders added 83,269 net shares at a 47% buy ratio, Dollar Tree saw 111k net shares added at a 59% buy ratio, and Gilead insiders bought 272k net shares while maintaining a 56% buy ratio against 35% sells.

Quick Scan

The 8 Names

1. Newmont Corporation (NEM)

Dividend yield: 1.0% | Payout ratio: 16% | 52w drawdown: 19%

FCF yield of 6.3% against a 1.0% dividend pegs the payout ratio at 16%, leaving $5.5 billion annually available for reinvestment or distribution expansion. ROIC at 30% and gross margin at 53% confirm operational efficiency in a sector where margin compression typically flags overextension.

Revenue growth of 21% reflects M&A-driven throughput expansion rather than organic production gains; the question is whether integration synergies hold when metal prices flatten. Net debt-to-EBITDA at negative 0.20 eliminates refinancing risk but also signals underutilized capital structure in a capex-intensive business.

Three executives including David Thornton, Peter Wexler, and Peter Toth filed Form 4 disclosures on May 4, though net insider activity over six months shows 3,502 shares sold. The disconnect between recent executive filings and the six-month net-sell position flags dilution or option-exercise activity rather than alignment buying.

2. Novartis AG (NVS)

Dividend yield: 3.3% | Payout ratio: 65% | 52w drawdown: 15%

FCF yield at 5.5% against a 3.3% dividend gives payout cover of 1.7×, and the five-year dividend CAGR of 7.2% shows consistent capital return while preserving balance-sheet flexibility. Gross margin at 76% is structural; biosimilars and CAR-T franchises are high-touch, high-value therapies that don't compete on manufacturing cost.

Normalized P/E at 20.8 against earnings yield of 4.8% leaves a spread of 44 basis points to the 10Y; not compressed, but not a margin-of-safety multiple when the 10-year earnings yield averages just 0.4%. The setup here is cash flow certainty priced at fair value, not a mispricing.

Net debt-to-EBITDA at 1.75× is manageable but higher than peers; Novartis funds R&D and business development through levered cash flow, so any late-stage trial miss or biosimilar pricing shock narrows the dividend-cover cushion faster than a fortress-balance sheet would.

3. Biogen Inc. (BIIB)

Dividend yield: n/a | Payout ratio: 0% | 52w drawdown: 7%

FCF yield of 7.1% with zero dividend paid means 100% of free cash is available for buybacks, bolt-on M&A, or eventual distribution. Net debt-to-EBITDA at 0.65× and interest coverage at 6.8× leave room to lever the balance sheet for pipeline acceleration without triggering covenant pressure.

Insiders added 83,269 net shares over six months at a 47% buy ratio against just 2% sells; Adam Keeney filed a Form 4 on May 5. The six-month dollar scale and asymmetry between buys and sells signal alignment, not option-exercise noise.

Revenue growth of 2.2% and gross margin at 76% show a mature base business; the question is whether Alzheimer's franchise expansion or rare-disease bolt-ons can reaccelerate the top line before the next patent cliff arrives. The multiple at 20× is priced for pipeline execution, not legacy-drug decay.

4. ConocoPhillips (COP)

Dividend yield: 2.7% | Payout ratio: 51% | 52w drawdown: 9%

FCF yield at 4.8% against a 2.7% dividend results in 51% payout, and shareholder yield of 3.4% captures both distributions and buybacks. ROIC at 13% and net debt-to-EBITDA at 0.73× confirm disciplined capital allocation in a sector prone to cycle-top overinvestment.

Insiders added 265,981 net shares over six months; Silvina Vatnick, Ricardo Jaramillo Mejia, and Luis Restrepo filed Form 4s on April 23. The concentration of filings and the 118% buy ratio against 98% sells flags conviction rather than programmatic diversification.

Revenue growth of 7.7% reflects higher realized prices and production mix, not reserve replacement; the setup depends on Brent holding above $70 and the Permian continuing to deliver sub-$40 breakevens. If either assumption breaks, the 51% payout ratio compresses margin for error faster than the balance sheet can absorb.

5. GSK plc (GSK)

Dividend yield: 3.6% | Payout ratio: 63% | 52w drawdown: 18%

FCF yield at 4.7% underpins a 3.6% dividend with 63% payout ratio, and gross margin at 72% reflects vaccine and specialty portfolios rather than generic exposure. ROIC at 20% and interest coverage at 11.8× confirm profitability on invested capital, and the 18% drawdown from 52-week highs has narrowed the P/E to 13.1× against an earnings yield of 7.7%.

The 10-year normalized earnings yield at 3.2% is 440 basis points below the current-year figure, signaling that trailing EPS reflects a cyclical peak or one-time gain rather than sustainable run-rate. The setup here is a payout supported by near-term cash flow; the question is whether the next five years compound at half the current yield.

Net debt-to-EBITDA at 1.37× and EV/EBITDA at 19.2× indicate a levered valuation relative to cash flow; any Zantac litigation overhang or RSV vaccine pricing reset tightens the dividend cushion before management can delever organically.